Targets › PDE3A
29 programs from 28 companies in 67 trials: 33 Phase 2, 13 Phase 3, 13 Phase 4, 8 Phase 1; Cardiovascular, Other, Genitourinary; next expected readout Nov 2026.
Cyclic nucleotide phosphodiesterase with specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Also has activity toward cUMP. Independently of its catalytic activity it is part of an E2/17beta-estradiol-induced pro-apoptotic signaling pathway. (UniProt, Q14432)
Open in Phaseline: the race on PDE3A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| St Joseph University, Beirut, Lebanon | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 4 | Lumbar Radiculopathy | Dec 2026 |
| Ottawa Heart Institute Research Corporation | Milrinone Phosphodiesterase 3A inhibitor | PDE3A | Phase 4 | Shock, Cardiogenic | Dec 2026 |
| Seoul National University Bundang Hospital | Cilostazol Phosphodiesterase 3A inhibitor | PDE3A | Phase 4 | Type 2 Diabetes; Type 2 Diabetes Mellitus (T2DM); Type 2 Diabets Mellitus | Dec 2026 |
| VA Office of Research and Development | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 4 | Diabetic Kidney Disease | Jan 2028 |
| Vastra Gotaland Region | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 4 | Takotsubo Syndrome | Dec 2028 |
| Massachusetts General Hospital | Theophylline Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 4 | PHP Ia | Apr 2030 |
| Zagazig University | Milrinone Phosphodiesterase 3A inhibitor | PDE3A | Phase 4 | Pulmonary Hypertension Due to Left Heart Disease | – |
| Beijing Tiantan Hospital | Y-4 tablets Integrin alpha-IIb/beta-3 inhibitor | PDE3A, ITGB3, ITGA2B, IL1R1 | Phase 3 | Ischemic Stroke, Acute; Aneurysmal Subarachnoid Hemorrhage; Acute Ischemic Stroke; Stroke Acute … | Dec 2026 |
| Al-Azhar University | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | Chronic Kidney Diseases | Dec 2026 |
| Tanta University | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | IBS - Irritable Bowel Syndrome; Rheumatoid Arthritis | May 2027 |
| NICHD Neonatal Research Network | Milrinone Phosphodiesterase 3A inhibitor | PDE3A | Phase 3 | Post-ligation Cardiac Syndrome | Jun 2027 |
| Tenax Therapeutics | Levosimendan (TNX-103) Phosphodiesterase 3 inhibitor; Troponin, cardiac muscle positive modulator | PDE3A, PDE3B, TNNC1, TNNI3, TNNT2 | Phase 3 | Pulmonary Hypertension Associated With HFpEF; Pulmonary Hypertension; Mechanical Ventilation; Cardiogenic Shock | Jun 2028 |
| Merck & Co. (MSD) | Ensifentrine (MK-5884) Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 3 | Pulmonary Disease, Chronic Obstructive | Apr 2029 |
| University of Washington | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | Medication-related Osteonecrosis of the Jaw | – |
| Beni-Suef University | pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | Embryo Transfer | – |
| Vanderbilt University Medical Center | Theophylline Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 2 | Pseudohypoparathyroidism | Dec 2026 |
| Mostafa Bahaa | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Epilepsy | Dec 2026 |
| Yunfeng Xia | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 2 | Restless Leg Syndrome Due to Uraemia | Dec 2026 |
| Ihab Elsayed Hassan | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Inflammatory Bowel Diseases | Jan 2027 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Ensifentrine (MK-5884) Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 2 | Pulmonary Disease, Chronic Obstructive, COPD; Non-cystic Fibrosis Bronchiectasis | Mar 2027 |
| Beni-Suef University | Aminophylline Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 2 | Acute Calculous Anuria; Pediatric Urolithiasis; Renal Stones | Mar 2027 |
| University Hospital, Limoges | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Medication-related Osteonecrosis of the Jaw (MRONJ) | Apr 2027 |
| MediciNova | Ibudilast (MN-166) Phosphodiesterase 4 inhibitor; Phosphodiesterase 3A inhibitor; Phosphodiesterase 10A inhibitor | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 2 | Amyotrophic Lateral Sclerosis | Apr 2027 |
| Stanford University | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 2 | Hypophosphatemia | May 2027 |
| Montreal Heart Institute | Milrinone Phosphodiesterase 3A inhibitor | PDE3A | Phase 2 | Right Heart Failure | May 2028 |
| M.D. Anderson Cancer Center | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Lymphedema; Fibrosis Syndrome | May 2029 |
| University Health Network, Toronto | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Non-Small Cell Lung Cancer | Nov 2031 |
| Medical College of Wisconsin | Theophylline Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 1 | Acute Kidney Injury | May 2027 |
Pseudohypoparathyroidism (2) Stroke Acute (2) Alcohol Use Disorder (2) Acute Kidney Injury (2) Head and Neck Squamous Cell Carcinoma (2) Pulmonary Hypertension Due to Left Heart Disease (2) Medication-related Osteonecrosis of the Jaw (1) Medication-related Osteonecrosis of the Jaw (MRONJ) (1) Amyotrophic Lateral Sclerosis (1) Hypophosphatemia (1) Epilepsy (1) Pulmonary Hypertension Associated With HFpEF (1)
small molecule (29)
Beni-Suef University (2) University of Washington (1) University Hospital, Limoges (1) MediciNova (1) Stanford University (1) Mostafa Bahaa (1) Tenax Therapeutics (1) M.D. Anderson Cancer Center (1) Seoul National University Bundang Hospital (1) Vastra Gotaland Region (1) VA Office of Research and Development (1) Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (1) NICHD Neonatal Research Network (1) Ihab Elsayed Hassan (1) Montreal Heart Institute (1) Vanderbilt University Medical Center (1) Beijing Tiantan Hospital (1) University of Pennsylvania (1) Ottawa Heart Institute Research Corporation (1) Al-Azhar University (1)
PDE4A (22) PDE5A (14) ADORA2B (11) ADORA2A (11) PDE4D (8) PDE4B (8) PDE4C (8) SLC29A1 (3) PDE6H (3) PDE3B (1) TNNC1 (1) TNNI3 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.